BioSpace News Archive

ViaNautis Bio, a groundbreaking nanomedicine company at the forefront of genetic therapies, announces the appointment of Dr Steven M. Altschuler as independent Chairman to its Board of Directors.

Aclaris Therapeutics, Inc. announced it will report financial results for the first quarter 2024 on Tuesday, May 7, 2024, after the closing of the U.S. financial markets.

SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, announced that Chief Financial Officer and Chief Operating Officer, Ross Muken, will present at the 2024 RBC Capital Markets Global Healthcare Conference in New York City on Tuesday, May 14, 2024, at 3:35 p.m. EDT.

Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, announced today it will release first quarter 2024 results after the market closes on Monday, May 13, 2024.

Clearside Biomedical, Inc., a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space, announced that its first quarter 2024 financial results will be reported on Thursday, May 9, 2024 after the close of the financial markets.

ProMIS Neurosciences Inc. announced the publication of a paper titled, “Relationship between therapeutic activity and preferential targeting of toxic soluble aggregates by amyloid-beta-directed antibodies,” in the online journal, bioRxiv.

LSL PHARMA GROUP INC. reported its financial results for the year-ended December 31, 2023.

Daré Bioscience, Inc., a leader in women’s health innovation, announced it has closed a royalty monetization transaction with XOMA LLC.

Palatin Technologies, Inc., a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced it will host a virtual KOL event on Wednesday, May 8, 2024 at 10:00 AM ET.

PAVmed Inc. announced that Veris and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, a National Cancer Institute-Designated Comprehensive Cancer Center, have executed a memorandum of understanding to implement a pilot program where cancer patients would be enrolled on the Veris Cancer Care Platform™.